167 related articles for article (PubMed ID: 26944437)
1. New potential chemotherapy for ovarian cancer - Combined therapy with WP 631 and epothilone B.
Bukowska B; Rogalska A; Marczak A
Life Sci; 2016 Apr; 151():86-92. PubMed ID: 26944437
[TBL] [Abstract][Full Text] [Related]
2. Why a Combination of WP 631 and Epo B is an Improvement on the Drugs Singly - Involvement in the Cell Cycle and Mitotic Slippage.
Bukowska B; Rogalska A; Forma E; Brys M; Marczak A
Asian Pac J Cancer Prev; 2016; 17(3):1299-308. PubMed ID: 27039763
[TBL] [Abstract][Full Text] [Related]
3. WP 631 and Epo B synergize in SKOV-3 human ovarian cancer cells.
Marczak A; Bukowska B; Rogalska A
Environ Toxicol Pharmacol; 2014 Jan; 37(1):256-66. PubMed ID: 24374386
[TBL] [Abstract][Full Text] [Related]
4. Caspases and ROS - dependent mechanism of action mediated by combination of WP 631 and epothilone B.
Rogalska A; Bukowska B; Marczak A
Anticancer Agents Med Chem; 2014; 14(9):1261-70. PubMed ID: 24913659
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. Early Activation of Apoptosis and Caspase-independent Cell Death Plays an Important Role in Mediating the Cytotoxic and Genotoxic Effects of WP 631 in Ovarian Cancer Cells.
Gajek A; Denel-Bobrowska M; Rogalska A; Bukowska B; Maszewski J; Marczak A
Asian Pac J Cancer Prev; 2015; 16(18):8503-12. PubMed ID: 26745109
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for advanced ovarian cancer: overview of randomized trials.
Thigpen JT
Semin Oncol; 2000 Jun; 27(3 Suppl 7):11-6. PubMed ID: 10952121
[TBL] [Abstract][Full Text] [Related]
9. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B.
Rogalska A; Marczak A; Gajek A; Szwed M; Śliwińska A; Drzewoski J; Jóźwiak Z
Toxicol In Vitro; 2013 Feb; 27(1):239-49. PubMed ID: 22995584
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
15. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin.
Rogalska A; Gajek A; Szwed M; Jóźwiak Z; Marczak A
Toxicol In Vitro; 2011 Dec; 25(8):1712-20. PubMed ID: 21896327
[TBL] [Abstract][Full Text] [Related]
16. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
17. [New aspects by the therapy of ovarian cancer--What changes after the ASCO-Meeting 2001].
Costa SD; von Minckwitz G; Wernicke K; Kaufmann M
Zentralbl Gynakol; 2002 Feb; 124(2):96-103. PubMed ID: 11935494
[TBL] [Abstract][Full Text] [Related]
18. Current status of chemotherapy for ovarian cancer.
Ozols RF
Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
20. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Bauknecht T; Meier W; Richter B; Kuhn W; Quaas J; Pfisterer J
J Clin Oncol; 1999 Jan; 17(1):46-51. PubMed ID: 10458217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
